Key Record Dates Identifier: NCT02606305
Brief Title: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

First Submitted : November 6, 2015
First Submitted that Met QC Criteria : November 13, 2015
First Posted : November 17, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : March 1, 2021
Last Update Posted : March 3, 2021